The American Medical Association (“AMA”) has announced an update to its medical codes which sets the stage to account for the development and administration of bird flu “vaccines” in anticipation of a potential avian influenza pandemic.
Developed and maintained by the AMA, the Current Procedural Terminology (“CPT”) codes standardise reporting of medical, surgical and diagnostic procedures performed by physicians and other healthcare providers, and are used for billing and insurance reimbursement purposes. So, the new code updates electronic healthcare systems across the US.
This new code which “is effective for use on the condition the H5N8 Influenza virus vaccine candidates receive emergency use authorisation” follows a pattern of the US government investing heavily in bird flu pandemic preparation efforts, including funding for the development of an mRNA-based pandemic influenza vaccine.
Bird Flu: CPT Code Update Readies U.S. Health Systems for New mRNA Jab Rollout Skipping FDA Approval Process
In anticipation of a coming avian influenza (bird flu) pandemic, the American Medical Association (“AMA”) on Friday 19 July announced an editorial update to the ‘Current Procedural Terminology’ (“CPT”) code set to account for the development and administration of bird flu “vaccines.”
The announcement came just days before World Health Organisation (“WHO”) Director Dr. Tedros Ghebreyesus stated the “next pandemic is a matter of when, not if.”
CPT is the leading medical terminology code set for describing healthcare procedures and services.
The new code updates electronic healthcare systems across the US.
“The provisional CPT code is effective for use on the condition the H5N8 Influenza virus vaccine candidates receive emergency use authorisation from the US Food and Drug Administration (FDA),” the AMA announcement reads. “The AMA is publishing the CPT code update now to ensure electronic systems across the US health care system are prepared in advance for the potential FDA authorisation.”
The controversial Emergency Use Authorisation (“EUA”) tactic allows drugs with no long-term safety data to be distributed to the public without receiving full FDA approval, as with covid-19 injections.
Back in May, Dr. Peter Marks, Director of the Centre for Biologics Evaluation and Research (“CBER”) at the FDA, confirmed his agency will skip the rigorous drug approval process for influenza bird flu vaccines.
The FDA intends to roll out bird flu jabs to the American public “as quickly as possible.”
No comments:
Post a Comment